Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06065371 · ClinicalTrials.gov registry record · Phase 1
Sacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy
A Phase 1 study of Gastrointestinal Cancer, sponsored by Henry Ford Health System.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT06065371: Recruiting Phase 1 study of Gastrointestinal Cancer, sponsored by Henry Ford Health System.
NCT06065371 is a Phase 1 study of Gastrointestinal Cancer that is actively recruiting participants, run by Henry Ford Health System. The registered enrollment target is 20 participants, below the 229-participant average among 49 other Gastrointestinal Cancer trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06065371, a Phase 1 study of Gastrointestinal Cancer, is actively recruiting participants, sponsored by Henry Ford Health System.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a Phase I study to evaluate the safety and tolerability of sacituzumab govitecan in combination with capecitabine for advanced gastrointestinal cancers after progression on standard therapy, and to assess correlation of outcomes with the biomarker Trop-2.
Primary Outcome
Recommended phase 2 dose (RP2D)
Conditions Studied
Interventions
- DRUG Capecitabine
- DRUG Sacituzumab govetican
Study Locations (1)
Michigan
- Henry Ford Cancer-Detroit - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2024-11-20 |
| Est. Completion | 2027-05 |
| Phase | Phase 1 |
What NCT06065371 shows while recruiting
NCT06065371 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 229-participant average among 49 other Gastrointestinal Cancer trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Gastrointestinal Cancer appearing as the primary indexed condition, and to 2 interventions - of which Capecitabine is the first listed.
NCT06065371 reports a single indexed study location in Michigan.
Frequently Asked Questions
What is clinical trial NCT06065371 about?
NCT06065371 is a clinical study titled "Sacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy". This is a Phase I study to evaluate the safety and tolerability of sacituzumab govitecan in combination with capecitabine for advanced gastrointestinal cancers after progression on standard therapy, and to assess correlation of outcomes with the biomarker Trop-2.
What is the current status of trial NCT06065371?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2024-11-20. Estimated completion is 2027-05.
What conditions does trial NCT06065371 study?
This clinical trial studies the following conditions: Gastrointestinal Cancer.
What interventions are being tested in trial NCT06065371?
The interventions under investigation include: Capecitabine (DRUG), Sacituzumab govetican (DRUG).
Who is sponsoring clinical trial NCT06065371?
This trial is sponsored by Henry Ford Health System, which has 234 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06065371 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastrointestinal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06065371's enrollment target sits among peer trials
20 44th of 49 higher than 5 of 49 other Gastrointestinal Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Gastrointestinal Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
RECRUITING · Phase 1
-
Individualized Response Assessment to Heated Intraperitoneal Chemotherapy (HIPEC) for the Treatment of Peritoneal Carcinomatosis From Ovarian, Colorectal, Appendiceal, or Peritoneal Mesothelioma Histologies
RECRUITING · Phase 1
-
Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)
RECRUITING · Phase 1
-
Neratinib and Fam-Trastuzumab Deruxtecan in Advanced Gastro-esophageal Cancer Patients
RECRUITING · Phase 1
-
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
RECRUITING · Phase 1
-
Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI